Switch theme
Sign up to access all valuation multiples
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
2007
100
LTM Revenue $30.7M
LTM EBITDA -$67.9M
$12.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bionano Genomics has a last 12-month revenue of $30.7M and a last 12-month EBITDA of -$67.9M.
In the most recent fiscal year, Bionano Genomics achieved revenue of $30.8M and an EBITDA of -$97.5M.
Bionano Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bionano Genomics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $36.1M | $30.8M | XXX | XXX | XXX |
| Gross Profit | $5.9M | $9.6M | XXX | XXX | XXX |
| Gross Margin | 16% | 31% | XXX | XXX | XXX |
| EBITDA | -$213M | -$97.5M | XXX | XXX | XXX |
| EBITDA Margin | -591% | -317% | XXX | XXX | XXX |
| Net Profit | -$133M | -$232M | XXX | XXX | XXX |
| Net Margin | -367% | -755% | XXX | XXX | XXX |
| Net Debt | n/a | $51.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Bionano Genomics's stock price is $5.
Bionano Genomics has current market cap of $14.5M, and EV of $12.0M.
See Bionano Genomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.0M | $14.5M | XXX | XXX | XXX | XXX | $-65.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Bionano Genomics has market cap of $14.5M and EV of $12.0M.
Bionano Genomics's trades at 0.4x LTM EV/Revenue multiple, and -0.2x LTM EBITDA.
Analysts estimate Bionano Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bionano Genomics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $12.0M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | -0.1x | XXX | XXX | XXX |
| P/E | -0.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBionano Genomics's NTM/LTM revenue growth is 2%
Bionano Genomics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Bionano Genomics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bionano Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bionano Genomics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -15% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -317% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -54% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -314% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 81% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 249% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bionano Genomics acquired XXX companies to date.
Last acquisition by Bionano Genomics was XXXXXXXX, XXXXX XXXXX XXXXXX . Bionano Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bionano Genomics founded? | Bionano Genomics was founded in 2007. |
| Where is Bionano Genomics headquartered? | Bionano Genomics is headquartered in United States of America. |
| How many employees does Bionano Genomics have? | As of today, Bionano Genomics has 100 employees. |
| Who is the CEO of Bionano Genomics? | Bionano Genomics's CEO is Dr. R. Erik Holmlin, PhD. |
| Is Bionano Genomics publicy listed? | Yes, Bionano Genomics is a public company listed on NAS. |
| What is the stock symbol of Bionano Genomics? | Bionano Genomics trades under BNGO ticker. |
| When did Bionano Genomics go public? | Bionano Genomics went public in 2018. |
| Who are competitors of Bionano Genomics? | Similar companies to Bionano Genomics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bionano Genomics? | Bionano Genomics's current market cap is $14.5M |
| What is the current revenue of Bionano Genomics? | Bionano Genomics's last 12-month revenue is $30.7M. |
| What is the current EBITDA of Bionano Genomics? | Bionano Genomics's last 12-month EBITDA is -$67.9M. |
| What is the current EV/Revenue multiple of Bionano Genomics? | Current revenue multiple of Bionano Genomics is 0.4x. |
| What is the current EV/EBITDA multiple of Bionano Genomics? | Current EBITDA multiple of Bionano Genomics is -0.2x. |
| What is the current revenue growth of Bionano Genomics? | Bionano Genomics revenue growth between 2023 and 2024 was -15%. |
| Is Bionano Genomics profitable? | Yes, Bionano Genomics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
